Cargando…

Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma

The anti-GD2 antibody dinutuximab beta (Qarziba(®)) has been added to the present standard of care for patients with high-risk neuroblastoma in Europe based on the positive results obtained in different studies. In both the first-line and relapsed/refractory settings, treatment with dinutuximab beta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balaguer, Julia, García Hidalgo, Laura, Hladun, Raquel, Márquez Vega, Catalina, Pérez Alonso, Vanesa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928814/ https://www.ncbi.nlm.nih.gov/pubmed/36504394 http://dx.doi.org/10.1007/s11523-022-00930-w

Ejemplares similares

Dinutuximab beta for neuroblastoma
Publicado: (2020)

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020)

Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
por: Spasov, Neofit, et al.
Publicado: (2021)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021)

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
por: Giljević, Jasminka Stepan, et al.
Publicado: (2022)

Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance
por: Barone, Giuseppe, et al.
Publicado: (2021)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
por: Wieczorek, Aleksandra, et al.
Publicado: (2022)

Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava
por: Achbergerová, Monika, et al.
Publicado: (2022)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
por: Cicek, Filiz, et al.
Publicado: (2020)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
por: Olgun, Nur, et al.
Publicado: (2022)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
por: Keyel, Michelle E, et al.
Publicado: (2018)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
por: Ladenstein, Ruth, et al.
Publicado: (2020)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
por: Cupit-Link, Margaret, et al.
Publicado: (2023)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry
por: El Amrani, Mohsin, et al.
Publicado: (2018)

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
por: Mastrangelo, Stefano, et al.
Publicado: (2021)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
por: Flaadt, Tim, et al.
Publicado: (2023)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
por: Ornell, Kimberly J., et al.
Publicado: (2020)

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
por: Lode, Holger N., et al.
Publicado: (2023)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
por: Keyel, Michelle E., et al.
Publicado: (2023)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
por: Lode, Holger N., et al.
Publicado: (2023)

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial
por: Flaadt, Tim, et al.
Publicado: (2023)

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
por: Zobel, Michael John, et al.
Publicado: (2020)

Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz et al
por: Mora, Jaume, et al.
Publicado: (2021)

Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora et al
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Targeting of epigenetic regulators in neuroblastoma
por: Jubierre, Luz, et al.
Publicado: (2018)

Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain
por: Liu, Xin‐Yuan, et al.
Publicado: (2022)

Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway
por: Wang, Huixue, et al.
Publicado: (2020)

Plasma dopamine-beta-hydroxylase in neuroblastoma.
por: Schöni, M., et al.
Publicado: (1984)

Serum dopamine beta hydroxylase in children with neuroblastoma.
por: Eldeeb, B. B., et al.
Publicado: (1983)

Response to “High CD44 expression is not a prognosis marker in patients with high-risk neuroblastoma”
por: Vega, Francisco M., et al.
Publicado: (2020)

Recent advances in the developmental origin of neuroblastoma: an overview
por: Ponzoni, Mirco, et al.
Publicado: (2022)

Biological Insight and Recent Advancement in the Treatment of Neuroblastoma
por: Rivera, Zoriamin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pj2mbbisa1tts2bees7c5dsu79